We appreciate Dr. Eyuboglu’s interest in our article but wish to clarify some key points. First and most importantly, we did not mean to imply that heart failure (HF) with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) can be considered a single entity in all respects. Indeed, our concluding statement in the abstract reads, “ from the standpoint of resource use , HF can be considered a single entity” (emphasis added), which is precisely what our results demonstrated. Second, as Dr. Eyuboglu states, pharmacotherapy can play an important role in the prognosis of HF, with differential effects on the reduction of poor outcomes between patients with HFpEF and HFrEF. In our study, patients with HFpEF were more likely to receive angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (48% vs 38%, p <0.001), β blockers (53% vs 38%, p <0.001), and diuretics (48% vs 37%, p <0.001) compared with patients with HFrEF. We chose not to include these variables in our multivariate models because of their strong correlation with blood pressure. In analyses not shown, inclusion of pharmacotherapies did not change any of the results presented. Therefore, although Dr. Eyuboglu is certainly justified in questioning whether the role of conventional medical therapy would affect our comparison of the prognosis of HFpEF and HFrEF, we wish to assure all readers that this was not the case in our data.